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1. Introduction
Food allergy is one of the leading causes of allergic disease and the main cause of anaphylactic
reactions and mortality due to allergic problems, producing important economic problems
and social restrictions for the affected patients and their families.
The increase in the prevalence and persistence of food allergy throughout the world has a
significant impact not only upon patient safety but also on quality of life and healthcare
expenditure. Indeed, food allergy constitutes a major public health problem.
The attitude or approach to food allergy has always been to avoid the cause and adopt
measures against adverse reactions in the event of accidental intake. However, in the last few
years a new management strategy has been explored: the active induction of food tolerance.
One of the most promising therapies is desensitization to specific food allergens through oral
or sublingual immunotherapy, and research in this field is advancing quickly for some
established allergens. In this respect, the technique has demonstrated its effectiveness, and its
transfer to clinical practice is presently undergoing evaluation.
This chapter addresses the epidemiology and natural history of food allergy, the mechanisms
of immune tolerance to foods, the forms of desensitization and induction of tolerance to
allergens with applications to foods, and affords an update on the experience gained with the
induction of tolerance to different foods, the respective protocols and guides, efficacy and
safety considerations, and adverse reaction risk factors. An evaluation is also made of the
current state of biological therapy utilization in conjunction with specific immunotherapy for
food allergens.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and eproduction in any medium, provided the original work is properly cited.
Lastly, a discussion is made of the opportunities and limitations facing the clinical use of the
specific immunotherapy in food allergy, and of the areas of future research.
2. Epidemiology of food allergy
Food allergy is a worldwide problem, affecting at least 1-2% of all adults and between 6-8% of
the pediatric population [1–3]. The reported prevalences are conditioned by the diagnostic
methods used, the patient ages considered, and also by genetic, ethnic, geographic and cultural
factors. Consequently, the published data differ greatly from one country to another [4].
The diagnostic methodology used exerts a great influence. In this respect, a recent metaanalysis
[5] found the self-reported incidence of allergy to cow’s milk (CM), egg, peanut or crustaceans
to be 12%-a figure that dropped to 3% when the diagnosis was established from double-blind,
placebo-controlled food challenge(DBPCFC) or provocation testing. In the case of cow’s milk,
between 1.2% and 17% of those surveyed claimed to be allergic, depending on the study. In
this regard, if the diagnosis was established by prick testing or the determination of specific
IgE, the frequency was found to be 2-9%, versus a prevalence of 0-3% when DBPCFC was the
selected diagnostic technique.
In the United States [6] it is estimated that 8% of all children will suffer food allergy, and that
40% of these patients will experience severe reactions, while 30% will be allergic to several
foods – peanut, cow’s milk and crustaceans being the most commonly implicated foods. In a
one-year of age Australian population, the prevalence of allergic individuals as established by
provocation testing (i.e., challenge-proven allergy) reached 10% [7].
The prevalence of food allergy appears to be increasing rapidly, particularly in the industri‐
alized world [8–10] and in widely different regions such as the United Kingdom [11], the
United States [12], Australia [13], Sweden [9] or China [14].
2.1. The most frequently implicated foods
The age of the studied population and the geographical setting exert a key influence upon the
types of foods that cause allergy. The most common cause of food allergy in pediatric patients
is cow’s milk, followed by egg (and peanut in the United States). In turn, crustaceans, nuts and
peanut become the most common causes of more serious allergic reactions among adults, since
allergy to cow's milk and egg disappears in approximately three out of every four patients,
while the opposite is observed for the rest of foods.
2.2. Cow’s milk
Allergy to cow’s milk is the most common type of food allergy in children, affecting 2-3% of
all individuals in this age group. Approximately one-half of all cases are mediated by IgE, with
the development of immediate allergic reactions which in some cases may prove systemic and
serious (e.g., anaphylaxis). The rest of the cases are not mediated by IgE, and are characterized
by generally less serious gastrointestinal problems-with the exception of FPIES (food protein-
induced enterocolitis syndrome).
Allergic Diseases - New Insights180
Most patients show a favorable course, with disappearance of the allergy in up to 83% of all
subjects by 5 years of age. The specific IgE levels are a good predictor of tolerance, though
recent publications indicate that longer periods of time are currently needed to acquire natural
tolerance, and that tolerance now develops in adolescence and not in the early schooling period
as was common in the past [15,16]. Despite measures of caution, accidental intake still occurs,
often on a day to day basis in the home [17], with the description of even fatal anaphylactic
reactions [18].
2.3. Egg
Allergy to chicken egg (usually to egg white) is the second most common form of food allergy
in pediatric patients, being observed in 1-3% of all children [19]. The underlying pathogenesis
is mainly IgE-mediated. Approximately two-thirds of all patients acquire natural tolerance
[13,20,21], though a recent study has evidenced the persistence of egg allergy in 42% of the
patients upon reaching adolescence [22]. This change in tendency may contribute to increase
the number of adults with allergy to egg. In this regard, it has been estimated that 0.2% of all
adults are allergic to egg [23], so this figure is likely to increase.
2.4. Peanut
Allergy to peanut is one of the most frequent forms of food allergy in western countries, and
can give rise to serious IgE-mediated reactions in response to even small intakes or exposure
levels. The condition is found in up to 1.8% of all children in the United Kingdom [24] and in
1.3% of the adult population in the United States [23]. When diagnosed by provocation or
challenge testing, the prevalence reaches 3% of all children in Australia [7]. The prevalence of
peanut allergy appears to be increasing, and most individuals continue to suffer allergy to this
food in adult life [25]. Indeed, only 20% of the affected patients overcome peanut allergy [26],
and the percentage of tolerant subjects is related to the degree of sensitization [27]. Over 15%
of all affected patients suffer accidental exposure on a yearly basis [28,29].
2.5. Multiple foods
Allergy to multiple foods is important, since up to 30% of all allergic children suffer allergy to
more than one food [6,30] – the magnitude of the condition increasing with the degree of atopy
of the patient. These patients have poorer quality of life than those with allergy to a single food
[31], and are at an increased risk of suffering nutritional deficiencies [32]. Likewise, patients
with allergy to multiple foods have lesser chances of acquiring natural tolerance to the
implicated foods [22].
3. Current treatment of food allergy
The traditionally recommended approach to the management of food allergy consisted of strict
avoidance of the causal allergen; early recognition of the allergic reaction; and the availability
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of adrenalin to deal with serious reactions. However it is known that strict avoidance is very
difficult to achieve, and is limited by difficulty in interpreting food labels [33] and by the
existence of hidden allergens in commercial foods [34]. Accidental intake is therefore common,
and can be expected to occur in up to 50% of all patients in the course of a two-year period,
even in very cautious patients. Undertreatment is moreover a common problem [35].
3.1. Management of anaphylaxis
The main risk posed by food allergy is the induction of IgE-mediated systemic reactions. In
this regard, food allergy is the leading cause of both anaphylaxis and mortality due to
anaphylaxis. Between 40-100% of all deaths attributable to anaphylaxis in patients with food
allergy are due to commercial foods or foods prepared outside the home [18,36,37]
Management includes teaching the patients and caregivers to quickly recognize the symptoms
of anaphylaxis and promptly self-inject insulin and notify the emergency care services [38].
However, difficulties are found regarding correct use on the part of the caregivers [39], and in
assuming the responsibility of care on the part of the patients [40] – particularly in the case of
adolescents [41,42]. In such patients, one-fourth of all anaphylactic episodes occur outside the
home. It is therefore necessary to instruct the caretakers in school on how to handle anaphy‐
laxis, and to reinforce self-care instructions among these adolescents [43].
4. Quality of life
The need for a strict avoidance diet, the high probability of accidental exposure, and the risk
of anaphylaxis in food allergies alters the life of the patients and their families, and generates
anxiety and psychosocial stress, with a negative impact upon quality of life [44–46], to an extent
greater than that observed with other chronic disorders of childhood [47,48].
This loss of quality of life affects even the daily relations of the patient, with an increased
frequency of bullying in such children [49]. Allergic children are also at an increased risk of
suffering abuse.
5. Economic costs
Food allergy implies an important economic cost [50], reaching an estimated 25 billion USD
each year in the United States – the largest part of this sum (approximately 20 billion USD)
being assumed by the families as direct costs, working hours lost, visits to the emergency
service, etc. [51]. The generated costs are not only of a personal nature but moreover also affect
the healthcare services, the food industry, the caregivers, and society as a whole [52].
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6. Immunology of food tolerance
The gastrointestinal tract (GIT) is constantly exposed to an enormous number of exogenous
antigens, including commensal bacteria and ingested proteins. In this respect, the GIT is the
most relevant site of exposure to antigens in the entire body, and therefore of antigen absorp‐
tion and presentation to the host.
An epithelial layer separates the allergens from the lymphocyte population, antigen-present‐
ing cells (APCs) and other immune cells of the lamina propria that globally conform the so-
called mucosa-associated lymphatic tissue (MALT). Within the latter, the dendritic cells (DCs)
interact with the food allergens, determining the outcome of the adaptive response (immunity
versus tolerance)[53]. In this respect, immune tolerance is defined as suppression of the
antigen-specific cellular or humoral immune response.
Following the intake of proteins with the diet, enzyme-mediated digestion reduces their
immunogenicity, probably through destruction of the conformational epitopes. However,
other foods sharing common characteristics (molecular weight < 70 kDa, linear epitopes, water
solubility) are resistant to both physical and chemical degradation, and thus maintain their
allergenicity upon reaching the small intestine. Under normal conditions, the intact macro‐
molecules are taken up by a transcellular transport mechanism, and the antigenic material is
deposited through the basolateral surface of the epithelial cell layer; as a result, a significant
amount of food allergens reach the systemic circulation following a meal.
Another antigen uptake mechanism consists of direct antigen presentation to the CD11c
+dendritic cell population. The function of these cells is related to macrophage activity, and
there is evidence that the CD11+macrophage population plays an important role in the T cell-
mediated antigen-specific response during the development of immune tolerance to food
antigens.
More recent evidence supports that impairment in regulatory T cell (Treg) induction and innate
immunity might also contribute to Th2 polarization in early life. Prospective birth cohort
studies have shown that IgE production in response to egg, milk, and peanut commonly occurs
even in healthy infants. In non-allergic subjects, this Th2 bias appears to be transient, and IgE
levels decrease, possibly through a counterbalancing induction of antigen-specific Th1
responses (i.e., IFN-γ); in contrast, these Th2 responses consolidate and strengthen in allergic
children, perhaps through the induction of IL-4 signaling [54].
A full 80% of all plasmatic cells are located in the intestine. The small bowel contains cell
generating pIgA (polymeric IgA)(80%), followed in order of prevalence by secretory pIgM
(polymeric IgM)(15-20%) and secretory IgG (3-4%). IgA deficiency in children has been
reported to be associated with an elevated frequency of food allergy. In this context, it has been
postulated that IgA plays a protective role in the context of food allergy [55].
The presence of antigen-specific IgG in the intestinal lumen can exert a significant influence
upon immunity to food and flora. IgG-mediated antigen uptake through FcRn in the neonatal
intestine is tolerogenic, and suggests that antigen exposure through breast milk would be a
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helpful preventative strategy, particularly when the mother has existing IgG antibodies to that
antigen. Once allergic sensitization has been established, it is not clear whether IgG-facilitated
antigen uptake through FcRn would amplify existing proallergic adaptive immune responses
or promote active immune tolerance. Studies are needed to address the influence of FcRn on
responses to food antigens [55].
Immunoglobulin E can be found in secreted form under the conditions of allergy and helminth
infection-this being associated with an epithelial receptor for IgE. IgE-facilitated antigen
uptake results in increased delivery of antigen to allergic effector cells, activates proinflam‐
matory pathways in intestinal epithelial cells, and enhances antigen delivery to dendritic cells.
IgE-facilitated antigen uptake by B cells can also have an adjuvant-like effect on the resulting
adaptive immune response.
This complex interaction among physical factors, antigen characteristics and timing, together
with the effects of innate immune stimulation, condition the development of oral tolerance
through a common pathway directly or indirectly influenced by APCs. It recently has been
shown that mucosal dendritic cells are probably the key element in determining allergic
sensitization versus tolerance in naïve subjects.
Multiple tolerance mechanisms probably intervene, and may include anergy or deletion of T
cells. There is evidence relating oral tolerance with the capacity of the mucosal dendritic cells
to induce positive forkhead box protein [Foxp3]+Treg cells in MLNs (mesenteric lymph nodes).
CD103, retinoic acid (RA), indoleamine-2,3-dioxygenase, co-stimulator molecules of the B7
family and TGF-β appear to act by allowing dendritic cells to induce such conversion. In
contrast, the dendritic cells of the lamina propria do not express CD103, and are proinflamma‐
tory. This suggests that tolerogenic dendritic cells could inhibit site-specific signaling of the
intestinal epithelium through interaction with E-cadherin (a CD103 ligand). This is probably
the microenvironment provided by the mucosa to allow antigen presentation resulting in
either inflammatory response or tolerance within the MLNs. Antigen-presenting cells other
than conventional dendritic cells might also participate in oral tolerance induction.
Oral tolerance might be operative through multiple mechanisms in multiple tissue compart‐
ments. For example, intestinal macrophages can also efficiently induce Foxp3+Treg cells in an
IL-10-, RA-and TGF-β-dependent fashion. Plasmacytoid dendritic cells, a specialized dendritic
cell subset known for their ability to produce vast quantities of type I interferons, can also
activate inducible Foxp3+IL-10. Integration of environmental information by dendritic cells
results in specific activation and differentiation of T cell subsets, including the Foxp3+Treg
cells, as the primary effectors of oral tolerance.
Repeated exposures to low doses of antigen are thought to be the optimal stimulus for the
development of Treg cells, which suppress immune responses through soluble or cell-bound
regulatory cytokines such as IL-10 and TGF-β. Natural CD4+CD25+Treg cells develop in the
thymus and express the specific transcription factor Foxp3+, which confers regulatory function
to these cells to block both Th1 and Th2 responses. Inducible regulatory T cells (iTreg) are
CD4+cells that can differentiate from naïve precursors, acquiring regulatory properties in the
periphery after exposure to antigen. In many cases these cells acquire the expression of Foxp3,
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and they exist in at least two forms distinguished by the antiinflammatory cytokines produced:
IL-10 (Tr1 cells) and TGF-β (Th3 cells). Whereas natural CD4+CD25+Treg cells are thought to
primarily govern peripheral tolerance to self-antigens, Treg cells are more likely responsible
for tolerance to exogenous substances, such as allergens [56].
Mechanistically, functional allergen-specific Treg cells can attenuate allergic responses
through: 1.-the suppression of mast cells, basophils, and eosinophils; 2.-the suppression of
inflammatory dendritic cells and induction of tolerogenic dendritic cells; 3.-the suppression of
allergen-specific Th2 cells, hence contributing to T cell anergy; and 4.-the early induction of
IgG4 and late reduction of IgE production. All of these mechanisms can be mediated through
the secretion of IL-10 and TGF-beta, or through cell contact-dependent suppression. The Treg
cells therefore appear to play an important role in tolerance following immunotherapy in food
allergy [57,58].
7. Active therapy against food allergy
Between 15-20% of all patients with allergy to cow’s milk and egg will remain allergic, while
those who acquire tolerance will take years to become tolerant. In contrast, most patients with
allergy to fish, crustaceans, peanut or nuts will remain allergic to these foods for life [59].
The health risks for such patients, the alterations in their diet, social discrimination, impaired
quality of life, and the costs generated by such illnesses have led to re-evaluation of the passive
management strategies with a view to establishing active treatment options – replacing the
management through avoidance paradigm with an active intervention approach based on
specific desensitization and tolerance of the causal food.
In this context, active intervention has been considered for years with the purpose of solving
this health problem, particularly in patients with a high risk of anaphylaxis and in those who
will not benefit from natural resolution of the problem. Such intervention involves nonspecific
therapeutic measures and, more recently, specific treatments for each type of food.
Immunotherapy would be a plausible option in view of its demonstrated efficacy in patients
with allergy to aeroallergens and stinging insect venom [60]. For this reason, the use of
immunotherapy in application to food allergens has been postulated for over two decades –
giving rise to a series of experiments and producing a body of knowledge over the last decade,
referred particularly to the oral route, which we will try to explain in this chapter.
Considering that non-IgE mediated allergy does not appear amenable to such treatment
strategies, we will only deal with IgE-mediated food allergy.
8. Immunotherapy in application to foods
The site of antigen administration and contact is important for the efficacy and safety of specific
food immunotherapy. According to the administration route involved, we can distinguish
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among four different types of specific food immunotherapy: subcutaneous immunotherapy
(SCIT), epicutaneous immunotherapy (EPIT), sublingual immunotherapy (SLIT) and oral
immunotherapy or specific oral tolerance induction (SOTI)[61].
8.1. Specific Subcutaneous Immunotherapy (SCIT)
There is extensive experience with the use of subcutaneous immunotherapy in application to
aeroallergens and insect venom – more than 100 years having gone by since the technique was
first developed – though very little experience has been gained to date with its use in appli‐
cation to food allergy. In patients with pollen-fruit syndrome [62], immunotherapy has been
found to be effective against aeroallergens that share antigenicity with certain plant foods [63–
65], securing desensitization to such allergens and foods. However, the utilization of specific
food allergens via the subcutaneous route (e.g., peanut), produced important [66] and serious
adverse reactions, with the death of one patient following error in the composition of the
placebo dose containing allergen. As a result, and despite evidence of a certain degree of
efficacy, these problems caused the early evaluation attempts to be suspended [67]. In effect,
since then, this specific immunotherapy administration route to treating food allergy has been
discontinued. However, the introduction of recombinant allergens, the elimination of epitopes
for IgE with the maintenance of T cell-recognized epitopes [68], immunotherapy with peptides,
DNA immunotherapy, and other advances that are currently in the preclinical investigation
phase, will make it possible to resume studies with this administration route.
8.2. Specific Epicutaneous Immunotherapy (EPIT)
Specific epicutaneous immunotherapy (EPIT) is based on the capacity of the Langerhans cells
of the epidermal basal layer to migrate and reach the lymph nodes, where they regulate the
cells implicated in allergic inflammation [69,70]. A pilot study in patients with allergy to cow’s
milk [71] demonstrated a modest increase in the amount of milk tolerated, with only local
symptoms, none of which proved serious. A recent phase IIa double-blind, placebo-controlled
(DBPC) efficacy study in patients with allergy to peanut (ARACHILD) [72] was able to secure
a more than 10-fold increase versus baseline in the tolerated levels after 18 months of treatment
in 67% of the patients. The study has currently been extended to 36 months, with good safety
results. Other studies involving this same administration route for the induction of peanut
desensitization are currently also in course.
8.3. Specific Sublingual Immunotherapy (SLIT)
Specific sublingual immunotherapy (SLIT), which makes use of the capacity of the Langerhans
cells of the oral mucosa to suppress allergic cell response [69,73,74], has been successfully
applied against aeroallergens in rhinitis and asthma [75,76]. In the same way as SCIT, the
technique has afforded improvement in patients with plant allergy exhibiting cross-allerge‐
nicity with certain pollens. In this regard, SLIT has been used against the latter [77] and against
latex – avoiding the increase in foods to which reactions occurred [78].
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Use has been made of SLIT with specific food allergens such as kiwi [79]. One case report
documented persistent tolerance after 5 years [80]. DBPC studies have been made with
hazelnut [81], with the maintenance of protection over the long term [82], and with peach [83],
in which tolerance could be increased 3-to 9-fold. At present, an observational study is
underway to evaluate the efficacy and safety of SLIT with Pru p3 extract in pediatric patients.
A pilot study with cow’s milk [84] was able to increase the tolerated amount of milk three-fold
in a group of 8 children. A placebo-controlled SLIT study with peanut [85] in turn secured a
10-fold increase in the amount of peanut that could be ingested without symptoms after 44
weeks of therapy in the active treatment group. A more recent placebo-controlled SLIT study
with peanut [86] found 70% of the patients to be able to ingest 5 g of peanut or increase the
tolerated amount up to 10-fold versus the amounts tolerated at baseline, after 44 weeks of
treatment.
8.4. Specific Oral Immunotherapy / Specific Oral Tolerance Induction (SOTI)
Specific oral tolerance induction (SOTI) is currently the most widely evaluated approach,
having exhibited effectiveness over the short and long term, though with limitations in relation
to its safety profile. Tolerance is taken to represent non-reactivity to the allergen even after a
period of time without contact with the allergen. In this regard, desensitization constitutes a
prior step, but does not guarantee lasting tolerance. SOTI is able to achieve desensitization in
a large percentage of patients – this being enough to avoid reactions secondary to accidental
ingestion and incorporation of the food to the diet. Such desensitization is possibly the most
important objective of the technique, since the number of patients that are able to achieve
permanent tolerance is considerably smaller. As a result, it has been proposed that SOTI should
actually be referred to as specific oral desensitization induction.
A prospective comparison of SOTI versus SLIT [87] has confirmed greater efficacy if SLIT is
followed by a SOTI phase involving high maintenance doses. The retrospective comparison
of SLIT and SOTI in application to peanut allergy [88] has shown greater efficacy with the latter
technique, though with more adverse effects. In this respect, it seems that SLIT is comparatively
safer but less effective than SOTI in application to foods.
Since SOTI is the most widely investigated type of specific immunotherapy in food allergy,
we will address the technique a little more in depth.
8.4.1. Mechanism of immune tolerance in SOTI
SOTI acts at intestinal dendritic cell level [89,56], lowering the specific IgE levels and increasing
the specific IgG4 titers, with an increase in IL-10, IL-5, IFN-γ, TNF-α and Foxp3 cells. Studies
involving T cell microarrays have shown inhibition oriented towards apoptosis at genetic level
[90]. The technique also reduces basophil IgE receptor production [91].
8.4.2. Regimens and phases in SOTI
The technique aims to induce desensitization and subsequent tolerance by administering small
amounts of allergens that cause no clinical manifestations or only mild manifestations. The
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amounts are gradually increased over time until the ingested allergen level reached is
considered to protect against adverse reactions and secure tolerance after ingestion of the food
over the following months.
Three phases can be distinguished during this process. On the first day an initial rush-type
rapid desensitization phase is established, followed by an escalation or up-dosing phase
involving daily administration of the tolerated dose in the home of the patient, with controlled
periodic up-dosing (usually on a weekly basis) until the maintenance or desensitization dose
is reached. This represents the start of the maintenance phase, in which the maximum dose
reached is ingested either daily or on alternating days over the subsequent months in order to
maintain desensitization and protection against accidental exposure, and to secure full
tolerance in at least some of the patients. This in turn must be confirmed through provocation
testing after an exclusion period or treatment cessation period of one or more months.
The different management protocols use these phases in different ways as regards the doses
and times. Some protocols prolong the initial rush phase to reach maintenance dosing within
about 5 days [92–94], avoiding the weekly up-dosing phase which usually covers 2-4 months.
This practice typically implies more adverse effects. In contrast, the initial protocols used by
Patriarca et al. did not use the rush phase and prolonged the escalation phase for more months,
with increments in the home of the patient introduced on a daily basis or every few days in
the form of very small amounts, until the full desensitization dose was reached [95]. The
mentioned group continues to maintain this protocol in modified form [96,97]. There is also
some experience with the use of a SLIT desensitization phase followed by SOTI [87] – this being
an option in those patients who fail to tolerate the initial rush phase. In other studies the rush
phase is prolonged to two days and the up-dosing or dose escalation phase to 16 weeks [98,99].
The authors use a one-day rush phase and a 10-week dose escalation phase.
The most recent protocols typically contemplate all three phases, and follow-up evaluation
after the last phase, which is essential in order to confirm tolerance.
8.4.3. Experiences and clinical trials with SOTI
8.4.3.1. Peanut
In a non-controlled SOTI study, 28 children between 1-16 years of age with peanut allergy were
randomized 2:1 to active treatment or placebo. Three patients in the active treatment group
abandoned the study due to adverse effects, while the rest reached the 4000 mg dose, and after
12 months were able to tolerate 5000 mg (20 peanuts), versus 280 mg in the control group
(p<0.001). Significant reductions were observed in the size of the prick test and in the specific
IgE and Th2 cytokine levels – with a significant increase in specific IgG4 titers and Treg cell
count [100].
In another study, 29 patients completed the protocol and were able to consume 3.9 g of peanut
protein, with a significant decrease in the size of the prick test and in basophil activation after
6 months of maintenance dosing. Specific IgE was seen to decrease, with a significant increase
in specific IgG4 between months 12-18 of this treatment phase, together with elevations in the
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levels of IL-10, IL-5, IFN-γ, TNF-α and Foxp3 T cells, with demonstration of inhibition oriented
towards apoptosis at genetic level [90].
In another non-controlled study, 23 patients with anaphylaxis due to peanut allergy diagnosed
by DBPCFC received SOTI in the form of a rush protocol during 7 days until a dose of 0.5 g
was reached. After 8 weeks of daily intake and a two-week avoidance phase, DBPCFC was
repeated, with tolerance of only 0.15 g of peanut. Twenty-two patients continued with the
maintenance phase, and after an average of 7 months, 13 of them (60%) reached the protective
dose, with a final tolerance of 0.25-4 g of peanut (initial tolerance being 0.02-1 g). Three of the
22 patients suspended intake during this phase. A significant increase was recorded in specific
IgG4, with a decrease in Th2 cytokine levels [101].
8.4.3.2. Cow’s Milk (CM)
A total of 22 children with allergy to cow’s milk were randomized 2:1 to SOTI with 500 mg of
CM protein (15 ml CM) daily during four months, or to placebo. At final challenge testing, the
active treatment group tolerated 5140 mg, versus 40 mg in the control group. The IgE levels
did not vary, though the IgG4 levels increased significantly in the SOTI group [102].
Another study selected 97 children with DBPCFC-diagnosed allergy to CM with serious
reactions and very high anti-CM IgE titers. Sixty patients reacted to very low doses. The
subjects were randomized 1:1 to SOTI or an exclusion diet. After one year of treatment, 36%
of the patients in the SOTI group were fully tolerant (> 150 ml), 54% were able to consume
limited amounts of milk (5-150 ml), and 10% were unable to complete the protocol because of
persistent respiratory or digestive problems. None of the control subjects passed the final
DBPCFC test. [103]
A case series has described CM desensitization as a result of a rush-type SOTI protocol in four
patients, with long-term desensitization being achieved in all cases [93].
A multicenter study involving 60 pediatric patients with a mean age of two years (range 24-36
months) randomized the subjects 1:1 to an exclusion diet or SOTI (2-day rush phase followed
by a 16-week escalation phase until reaching a maintenance dose of 200 ml of CM). After one
year, 90% of the patients in the SOTI group were fully tolerant, versus 23% of the patients in
the exclusion diet group [98].
Another study randomized 30 patients diagnosed with CM allergy by DBPCFC to SOTI or
placebo (soya milk), with an 18-week up-dosing phase and no prior rush period. Thirteen
patients were maintained in the SOTI group, of which 10 reached the final dose of 200 ml (77%).
None of the control subjects passed the DBPCFC test [104].
Thirteen patients with CM allergy were subjected to SOTI with no initial rush phase and with
an 18-week escalation period until a dose of 200 ml of CM was reached. The three controls
received soya milk. Tolerance was achieved in 8 of the patients in the SOTI group (7 cases
of full tolerance and one partial tolerance), while the controls maintained DBPCFC positivi‐
ty [105].
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In another study, 28 children between 6-14 years of age with CM allergy (36% of an anaphy‐
lactic type) were recruited after oral provocation testing and randomized in a double-blind,
placebo-controlled SOTI study. Sixteen out of 18 patients in the active treatment group and 8
out of 10 in the placebo series completed the study. After one year of SOTI, 81% of the children
consumed 200 ml of CM or equivalent products. After confirming the absence of tolerance
among the controls, the latter were enrolled in a similar protocol and were seen to tolerate 200
ml of CM after 6 months. After 3.5 years, tolerance was maintained in 79% [106].
Lastly, in another study, 60 children aged between 13 months and 6.5 years were randomized
to SOTI or an exclusion diet. After 6 months, 89% of the patients in the active treatment group
tolerated 200 ml of CM, versus 60% of the controls (p<0.025). A decrease in the size of the prick
test was recorded in the active treatment group, while the size was seen to increase among the
controls [107].
8.4.3.3. Egg
A total of 55 patients with egg allergy were included in a randomized, double-blind, placebo-
controlled trial. Forty patients received SOTI. Of these, 55% passed a 5 g oral egg white powder
provocation test after 10 months, versus none of the individuals in the control group. In turn,
75% of the subjects in the active treatment group passed a 10 g oral provocation test after 22
months. Desensitization was associated to a decrease in specific IgE, an increase in IgG4 after
10 months, a reduction in basophil activation, and a decrease in the size of the prick test after
22 months [108].
Eighty-four patients with egg allergy that tolerated up to 1 g of raw egg white were randomized
to SOTI or an avoidance diet. After 6 months, 69% of the patients in the active treatment group
and 51% of the controls passed a oral provocation test, and the mean size prick test size and
specific IgE titers decreased significantly in the active treatment group. Furthermore, the
patients subjected to SOTI who failed to pass the provocation test had comparatively greater
tolerance and lesser severity of symptoms [107].
Of 19 patients between 4-14 years of age who started SOTI for egg allergy, 16 achieved full
tolerance (85%), being able to consume a 10 g dose of powdered pasteurized egg (equivalent
to one egg). In addition, a decrease was recorded in the population of effector-memory CD4+T
cells, with an increase in a subclass of CD4+T cells with a hypo-proliferative and non-reactive
phenotype [109]. These authors also recorded an increase in Treg cell count in those individuals
who reached tolerance [110].
In a study comprising 72 patients between 5-15 years of age, the presence of egg allergy was
confirmed by open oral challenge testing. Forty subjects were randomized to SOTI with
powdered pasteurized egg – tolerance being achieved in 92.5% of them, and in 21.8% of the
controls [111].
Another study involving 8 patients documented desensitization in 6 subjects (75%) [112].
In a retrospective review of 43 children with egg allergy, 30 were found to be willing to
participate in a SOTI study with egg, involving maintenance of the maximum tolerated dose
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two or three times a week. The 13 patients who declined to participate conformed the control
group. Nine of the 30 children in the active treatment group reached tolerance of one egg after
one year of SOTI – a figure that was seen to increase to 17 out of 30 subjects after two years of
treatment. In comparison, none of the controls achieved tolerance. Of the 14 desensitized
patients that could be followed-up on, 11 reached full tolerance [113].
A randomized and controlled study recorded partial tolerance (10-40 ml of raw hen’s egg
emulsion) in 90% of the patients (n=9) subjected to SOTI with egg during 6 months, versus
none of the controls [114].
8.4.3.4. Metaanalyses
A metaanalysis of SOTI with cow’s milk included 5 randomized controlled trials (RCTs) and
5 observational studies that met the inclusion criteria. The RCTs comprised 218 patients and
showed that oral immunotherapy versus an elimination diet increased the probability of
acquiring full tolerance to cow’s milk [relative risk: 10.0 (95%CI: 4.1-24.2)]. The adverse effects
of immunotherapy included frequent local symptoms (16% of the doses), mild laryngeal spasm
[relative risk: 12.9 (1.7-98.6)], mild asthma [rate ratio: 3.8 (95%CI: 2.9-5.0)] and reactions
requiring oral corticosteroids [relative risk: 11.3 (95%CI: 2.7-46.5)] or intramuscular adrenalin
[relative risk: 5.8 (95%CI: 1.6-21.9)]. The findings of the observational studies were consistent
with those of the RCTs. The metaanalysis concluded that larger RCTs are needed [115].
Another metaanalysis of SOTI with cow’s milk selected 16 publications, of which 5 were clinical
trials. The studies were generally small and presented methodological inconsistencies, with
low quality evidence. Each study used a different SOTI protocol. A total of 196 pediatric
patients were studied (106 subjected to SOTI and 90 controls). Sixty-two percent of the patients
in the SOTI group and 8% of the controls reached tolerance of about 200 ml of cow’s milk
[relative risk 6.61 (95%CI: 3.51-12.44)]. In addition, another 25% of the subjects in the SOTI
group achieved partial tolerance (10-184 ml), versus none of the controls [relative risk 9.34
(95%CI: 2.72-32.09)]. None of the studies evaluated the patients some time after immunother‐
apy suspension. Adverse reactions were common, affecting 92% of the patients, though most
were mild and of a local nature. One out of every 11 patients receiving SOTI required intra‐
muscular adrenalin. The studies conducted to date have involved small numbers of patients,
and the quality of the evidence is generally low. The current data show that SOTI can lead to
desensitization in the majority of individuals with cow’s milk allergy, though the development
of long-term tolerance has not been established. A major drawback of such therapy is the
frequency of adverse effects, although most are mild and self-limited. The use of parenteral
epinephrine is not infrequent [116].
Regarding SOTI for allergy to cow’s milk, achieving desensitization or even tolerance to cow’s
milk does not imply desensitization to milk from other mammalian species to which the patient
may be sensitized [117,118] – a circumstance observed in 25% of the cases in one study [119].
Consequently, the exclusion of milk and milk products from other species must be maintained
if exposure testing does not confirm the existence of tolerance to such foods.
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8.4.3.5. Other foods
Individual SOTI studies have yielded positive results in reference to other foods such as tomato
[94], celery [120], apple [121] or wheat [122,123].
8.4.3.6. Multiple foods
A field of great interest refers to the study of simultaneous allergy to multiple foods (up to 5),
since one-third of all patients with food allergy are allergic to two or more different foods. In
this respect, a trial has been carried out in 40 patients [124], of which 15 were allergic only to
peanut, while 25 were allergic to more foods. The patients received up to 4 g of each food
during the maintenance phase, and tolerance was seen to increase 10-fold versus the initial
DBPCFC dose. The same authors have conducted a study of desensitization to multiple foods
with omalizumab therapy, which allowed a shortening of the dose escalation phase [125].
8.4.3.7. Global metaanalyses
A metaanalysis of 33 case reports and 21 trials (18 RCTs and 3 controlled clinical trials) revealed
a substantially lesser risk of allergic food reactions in those individuals subjected to SOTI
[relative risk 0.21 (95%CI: 0.12-0.38)]. The immunological data showed a significant decrease
in prick test size and an increase in the specific IgG4 titers. The risk of local reactions was seen
to increase (in the form of mild oropharyngeal and gastrointestinal manifestations)[relative
risk 1.47 (95%CI: 1.11-1.95)], though no significant increase in systemic reactions was observed
[relative risk 1.08 (95%CI: 0.97-1.19)]. The authors concluded that there is strong evidence that
oral immunotherapy is able to induce immune changes and promote desensitization to
different foods. However, oral immunotherapy should not be used outside the defined
experimental conditions [126].
9. Safety
The side effects associated to SOTI are generally mild or moderate, with a predominance of
oropharyngeal manifestations that are easy to deal with [100–102,127,128]. However, more
serious reactions have also been reported, such as generalized urticaria / angioedema,
wheezing and dyspnea, laryngeal edema, intense abdominal pain and recurrent vomiting. This
latter adverse effect is the most limiting problem, preventing the continuation of SOTI in
10-15% of the patients [129].
There have been reports of eosinophilic esophagitis during the maintenance phase in patients
who did not have this problem before SOTI [130]. Although large series report a low incidence
(2%), in our experience the problem may be more frequent (10% in a small series of patients).
In this respect, the suspicion of eosinophilic esophagitis should be reinforced in cases with
classic symptoms of retroesternal pain, dysphagia, or less specific like recurrent cough or
digestive discomfort.
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In a study of SOTI with peanut [100], most patients suffered some symptoms. During the first
day of the up-dosing phase, two subjects abandoned the study, another two made use of
adrenalin, and 47% developed symptoms requiring antihistamines. Symptoms were observed
in 1.2% of the 407 doses during the escalation phase. Despite this observation, however, 16 of
the 19 patients subjected to SOTI were able to tolerate 4000 mg with only minimal adverse
effects. Likewise, in SOTI with cow’s milk, 45% of the doses produced symptoms, versus 11%
in the placebo group – most manifestations being mild and of an oropharyngeal nature [102].
During the first year of SOTI with egg, 25% of the 11,860 active treatment doses were associated
with symptoms, versus 4% of the 4018 placebo doses [127].
The frequency of adverse reactions is 10 times greater if the patient is moreover asthmatic [17].
9.1. Triggering factors
Viral infections, menstruation and physical exercise have been associated with reductions in
the tolerance threshold among patients who are already receiving SOTI maintenance doses
[131]. The development of other acute disease conditions may also require temporary SOTI
dose adjustment [101]. In a long-term SOTI follow-up study, 22% of the patients with allergy
to cow’s milk who had previously completed SOTI and had passed provocation testing with
the food reported limitations in milk intake due to symptoms often associated with physical
exercise (25%) and disease processes (6%) [132].
Rush-type SOTI protocols designed to shorten the interval required to reach maintenance
therapy have been associated to an increase in the incidence of undesired symptoms and
adrenalin use [103,101, 133, 134].
9.2. Prevention
It is advisable to avoid physical exercise in the hours before and after administration of the
dose, and to temporarily reduce the amount ingested by 50% in the case of viral disease or
respiratory symptoms. It is also advisable to administer the dose with other foods in order to
avoid gastrointestinal adverse effects.
Antihistamines have been used as premedication, and a study has used antileukotrienes to
control the gastrointestinal manifestations [135].
Thus, SOTI appears to be effective in securing desensitization, but it is not without risks.
Different metaanalyses indicate that the existing body of information is still insufficient to
guarantee the efficacy of the technique, and concern is still expressed about the safety of SOTI.
In this respect, further studies are recommended before considering transfer of the technique
from the experimental setting to clinical practice [115,116,126,136–138].
10. Long-term outcome
Does desensitization to a food imply long-term tolerance or only temporary tolerance?
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Although a considerable number of years have gone by since the first inductions of oral
tolerance to food were performed, few controlled studies have examined what happens after
several years of SOTI. Such information is crucial in order to define the frequency with which
full tolerance is achieved, as well as to identify the underlying patient-related factors involved,
and characterize the different desensitization options.
A communication published in 2005 [139] reported the loss of tolerance in two patients after
a two-month exclusion period following tolerance of the allergen maintenance dose during
several months (cow’s milk allergy with 27 weeks of tolerance of the 100 ml dose in one case,
and egg allergy with 39 weeks of tolerance of half an egg in the other). In turn, a third patient
who took 52 weeks in reaching the maximum dose again developed symptoms after four weeks
of exclusion. In these individuals the specific IgE titers did not exceed class IV. The authors
postulated that tolerance is dependent upon a series of variables such as the baseline tolerance
level, the duration of SOTI, the elimination diet involved, and the course of the illness at
individual level. Patients with a low probability of natural remission of their allergy may
require long-term maintenance therapy. There is little information on the interval between the
doses in the maintenance phase needed in order to preserve the acquired tolerance, though
for safety reasons, daily intake should be recommended.
A study published in 2007 [140] reported the follow-up data corresponding to four patients
who had undergone desensitization to cow’s milk three years earlier. Three of them were found
to have no detectable levels of specific IgE against casein, and presented no symptoms during
intake – though no exclusion period followed by reintroduction of the allergen had been
applied to ensure definitive tolerance.
The first long-term follow-up study on patients with cow’s milk allergy [141] revealed that
86% of the individuals reached desensitization (18 out of 21 patients), and tolerance persisted
in 14 out of 20 individuals (70%) upon evaluation an average of four years and 8 months after
the start of desensitization [142]. In addition, none of the patients needed to use adrenalin.
Since no control groups were established, these studies could not rule out the possibility that
tolerance in some of these individuals may have been attributable to natural mechanisms, and
were unable to establish whether tolerance persisted after the cessation of daily allergen intake.
In another study [143], 15 patients with successful induction of desensitization to cow’s milk
were subjected to oral provocation after 13 to 75 weeks with doses of 16 g. This dose was
tolerated by 6 of the patients, though here again there was no prior exclusion period. During
the follow-up period, adverse reactions were recorded that required adrenalin injection on 6
occasions (0.2% of the doses).
In a much larger patient sample [144], 66 subjects were diagnosed with allergy to cow’s milk
by DBPCFC (including 44 anaphylactic cases). Initial tolerance was achieved in 64 patients
(97%) – complete in 51 (> 150 ml) and partial in 13 (5-150 ml) – and was seen to persist after
one year of follow-up, with significant reduction of the specific IgE titers and of the size of the
prick test. As in the above studies, tolerance was not evaluated after an exclusion period.
In another study [145], following SOTI with egg or milk during a mean period of 21 months,
tolerance as demonstrated by DBPCFC was recorded in 36% of the patients two months after
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suspending SOTI. Surprisingly, tolerance in the control group reached 35%, indicating a lack
of efficacy of SOTI in achieving tolerance. In another non-controlled study, 7 patients received
SOTI with egg [146], and four of them passed DBPCFC testing after 24 months. In turn, two
of these four individuals passed a second DBPCFC test three months after suspending SOTI.
The commented relatively low yet promising success rates in inducing tolerance were
improved upon in a follow-up study [112] involving a SOTI dosing regimen in which the
maintenance dosage was increased stepwise until the levels of specific IgE against egg were <
2 kU/l. At this point DBPCFC was performed, and those patients who passed the test again
underwent DBPCFC one month after suspending SOTI. The 6 patients that passed the first test
also passed the second test.
Another study [87] first administered sublingual immunotherapy (SLIT) with milk, followed
by patient randomization to either continuation with SLIT or conversion to SOTI with two
different maintenance doses during 80 weeks. Six weeks after the end of immunotherapy, one
of the 10 patients in the SLIT group (maintenance dose 7 mg/day) was found to be tolerant,
versus three of the 10 patients administered 1000 mg of milk as maintenance in SOTI, and 5 of
the 10 patients administered 2000 mg of milk as maintenance in SOTI. Although this was a
non-controlled study with few patients, the results obtained support the idea that higher doses
and longer durations of immunotherapy can afford a sustained lack of allergic responses after
the end of therapy, or tolerance of the allergen.
A placebo-controlled study of SOTI with egg [127], involving 40 children in the active treatment
group and 15 in the placebo group, recorded desensitization in 75% of the patients after 22
months, with a 28% tolerance rate after 24 months as established by DBPCFC performed two
months after the end of SOTI. None of the controls passed the provocation test after 10 months,
though they were not again subjected to oral challenge after 22 or 24 months – except one
subject with specific IgE levels of < 2 kU/l, who failed to pass the test. After 30 to 36 months of
follow-up, those patients who had acquired tolerance were seen to retain tolerance. This study
suggests that approximately one-quarter of all children with egg allergy achieve tolerance after
two years of SOTI – though the absence of provocation testing after two years in the control
group may complicate interpretation of the data – particularly in view of the high degree of
spontaneous tolerance registered among the controls [147].
In another study, after SOTI and 5 years of maintenance therapy with 4000 mg of peanut, 50%
of the patients passed oral provocation testing and were able to incorporate peanut to their
diet without restrictions [148].
11. Biological therapies associated to SOTI
In the course of the induction of oral tolerance to foods, patients may experience serious
adverse effects (e.g., anaphylaxis) or problems of lesser magnitude but which preclude
desensitization in 10-20% of the cases. This raises doubts not only about the safety of such
techniques but also as regards their efficacy in application to patients with antecedents of food-
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induced anaphylactic reactions, which are precisely the individuals that could benefit most
from desensitization or even tolerance.
For these reasons, different authors have recommended the use of a protective “umbrella”
during the initial phases, in which IgE-mediated allergic reactions are most frequent, with a
view to avoiding at least the most serious incidents.
11.1. Omalizumab
The availability of a humanized anti-IgE monoclonal antibody marked as omalizumab
(Xolair®, Genentech / Novartis) has allowed its use to prevent adverse effects – particularly
anaphylaxis – in those patients who because of their degree of sensitization or seriousness of
previous adverse reactions are at particularly high risk. In addition to improving patient safety,
such preventive treatment would result in improved efficacy, since it would allow us to reach
doses sufficient to ensure complete desensitization and possible subsequent tolerance [149].
On the other hand, under this type of protection against anaphylaxis, we could shorten the
escalation or up-dosing period and even reach doses higher than those previously used.
Omalizumab is a recombinant anti-IgE monoclonal antibody (anti-IgE mAb) with a molecular
weight of 150 kDa; 95% of the antibody is derived from human kappa IgG1, to which certain
murine complementary determinant regions are coupled. These in turn bind selectively and
with high affinity to the CHε3 domain of the Fc of IgE, preventing binding of this domain to
the high-affinity IgE receptors (FcεRI) of mast cells and basophils – thus inhibiting the release
of mediators by these cells through Fab binding to the antigen. Binding to the low-affinity
receptors (FcεRII) of dendritic cells, T cells, eosinophils and other cells related to allergic
inflammation is also inhibited.
The absence of binding to these receptors also down-regulates the expression of IgE receptors
(FcεRI) on the part of mast cells and basophils, which is dependent upon the levels of IgE. On
the other hand, the antigen-presenting cells (APCs), i.e., dendritic cells, also reduce their
activity [150], and the formation of Th2 lymphocytes is consequently not stimulated. The
basophils also experience a change in activity, paradoxically increasing their sensitivity to the
allergen, but maintaining lowered activity in the presence of a specific IgE / total IgE ratio of
< 4% [151,152].
The circulating anti-IgE/IgE complexes do not activate complement, and by keeping the
antigen-binding fraction free, are able to capture antigens from the bloodstream – preventing
them from reaching the specific IgE already bound to the cells.
One week after the start of treatment with anti-IgE mAb, basophil FcεRI expression is strongly
suppressed, while mast cell FcεRI expression is suppressed after 10 weeks [153]. This rapid
basophil suppression, together with the clinical improvement, reflects the importance of these
cells [154,155].
After the first hour of treatment with omalizumab, the free IgE titers in blood decrease linearly
with respect to the dose, a maximum effect being observed within 6 days, when more than
96% of the IgE levels are cleared from plasma – though total IgE increases because the half-life
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of the IgE-Anti-IgE complex is longer than that of IgE. The half-life of omalizumab is about 3-4
weeks [156].
11.2. Administration regimen and dose
The dose is established according to the instructions of the manufacturer in relation to the total
IgE titers and patient body weight. In this regard, the minimum dose is 0.016 IU/kg/IgE
(IU/ml)/4 weeks, in fractionated subcutaneous doses if needed [157].
It is estimated that 9 weeks are needed to reach the maximum effect, reduction of IgE and a
decrease in the expression of its receptors. A clinical trial involving asthmatic patients found
the clinical response to manifest after 16 weeks of therapy in most patients (158], though a
study in children and adolescents found the maximum effect to manifest after four weeks of
treatment (159,160]. Differences in criterion and patient population may account for this
discrepancy. Most studies establish a minimum treatment period of 8 weeks prior to the start
of induction therapy. The posterior coverage period varies, but corresponds at least to the
interval required to reach the maximum maintenance dose. Treatment cessation has been
abrupt, and the protective activity is known to cease completely within about three half-lives
(some 9-12 weeks). Stepwise cessation over time and/or dose could result in a prolongation of
the protective action without incurring in major costs increments.
11.3. Clinical applications
Soon after the marketing of omalizumab, the use of these anti-IgE antibodies in food allergy
was considered [161]. Data evidencing its benefit referred to food tolerance were obtained in
patients who received the drug for asthma control, and who were seen to be able to consume
a larger amount of foods to which they were known to be allergic. Indeed, the patients were
able to start consuming some foods which they were previously unable to consume even in
very small amounts.
The usefulness of omalizumab in avoiding IgE-mediated allergic reactions other than allergic
asthma, such as for example food allergy, has been evidenced in different studies [162,163].
The drug has been shown to be effective in raising the oral provocation sensitivity threshold
among patients with peanut allergy, when used in monotherapy [155,164,165].
The protective activity of omalizumab has been confirmed in immunotherapy for allergic
rhinitis [166,167] and asthma [168]. Its utilization in rush immunotherapy [169], involving an
increased frequency of systemic adverse reactions, afforded increased protection, including
protection against anaphylaxis, when administered during the 9 weeks prior to immunother‐
apy and then for 12 months concomitant to immunotherapy. In this respect, omalizumab was
seen to be superior to the use of antihistamines as premedication. Likewise, increased efficacy
of immunotherapy has been documented in patients receiving anti-IgE mAb.
11.4. Clinical trials with omalizumab and SOTI
The above considerations have led to the use of omalizumab pretreatment in food tolerance
induction protocols [170]. To date, only non-controlled double-blind pilot studies involving
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few patients are available, though several randomized, double-blind, placebo-controlled trials
are currently underway.
The first published study to report a possible role for omalizumab administered together
with oral immunotherapy in allergic patients [171] assessed the usefulness of the drug in
inducing tolerance to cow’s milk in the context of a phase I pilot trial involving a small
patient  sample.  Evaluation  of  the  immunological  changes  revealed  the  inhibition  of
cutaneous  mast  cells  and  peripheral  blood  basophils  in  a  non-specific  allergen  manner
during therapy with omalizumab, and in an antigen-specific manner after completing the
milk desensitization protocol [172].
Thirteen patients with peanut allergy confirmed by DBPCFC participated in a pilot trial
involving pretreatment with omalizumab during 12 weeks, after which the drug was contin‐
ued in combination with the immunotherapy up-dosing phase for another 8 weeks [173]. This
made it possible to increase the initial peanut dose without major side effects, and to shorten
the weekly up-dosing phase. With the dose of the first day (992 mg of peanut flour, equivalent
to about 2 peanuts), the patients could be protected against anaphylactic reactions caused by
accidental ingestion of the allergen. Within 8 weeks, the maintenance dose of 4000 mg was
reached in 12 out of 13 patients, with tolerance after 30-32 weeks of 8000 mg as evidenced by
DBPCFC – this dose being 160-400 times greater than the dose causing symptoms at first
DBPCFC testing. Fifty-four percent of the patients (7 out of 13 individuals) suffered no adverse
reactions during the first rush phase, while the rest experienced grade 1 effects requiring
antihistamine use in only two patients. During the weekly up-dosing phase, 49 adverse effects
were documented, of which 97% corresponded to grade 1 and none to grade 3. During
maintenance therapy, without the administration of omalizumab, a total of 17 adverse effects
were recorded, two of which corresponded to grade 3. Those patients that experienced adverse
effects after suspending omalizumab had higher specific IgE titers both at the end and at the
start, as well as a larger prick test size. The prolongation of omalizumab in patients of this kind
was thus proposed.
Another non-controlled phase I study used omalizumab during 16 weeks, including 8 weeks
as pretreatment, in the induction of tolerance to different foods in combination with oral
immunotherapy [174]. This management strategy allowed rapid desensitization using higher
starting doses than those used in another trial carried out by the same authors [175], involving
up to 5 foods at once, and with no grade 2 (moderate) or grade 3 (severe) symptoms during
the up-dosing phase. Adrenalin proved necessary in only one case, during the maintenance
phase (representing 0.01% of the administered maintenance doses).
11.5. Side effects of omalizumab
These antibodies have been reported to cause side effects [156,157] – the most important being
local inflammatory reactions. Anaphylaxis has been reported in 0.2% of the patients. It has
been suggested that such treatment should be administered in an appropriate healthcare
setting, with an adequate period of observation after administration (2 hours on the first
occasion and half an hour with the subsequent doses), with the availability of preloaded
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adrenalin [176,177]. A recent study has observed no increased risk of tumors associated to
long-term treatment [178]. In contrast, the risk of parasitic infestations appears to increase;
treatment in high-prevalence areas therefore should be restricted.
Another very important aspect to be taken into account is the cost-effectiveness ratio, with a
view to ascertaining whether the treatment is acceptable from the healthcare and insurance
perspectives. No such data referred to the specific therapeutic indication of food allergy have
yet been obtained, however.
Further clinical data are currently needed, involving double-blind, placebo-controlled trials,
as well as cost-effectiveness analyses, in order to establish the recommendations for use in
concrete patient groups as treatment in combination with SOTI, such as for example:
• Patients at particularly high risk due to increased sensitivity (usually associated to increased
clinical reactivity) and/or who have suffered serious reactions to the food allergen
• Patients unable to reach levels considered necessary to ensure desensitization
• Protocols involving a rush phase and rapid up-dosing
• Patients undergoing desensitization to several foods at the same time
11.6. Interferon-γ and SOTI
Few data are available on the usefulness of interferon-γ in combination with SOTI, though the
preliminary results are encouraging [179].
12. Conclusion
Immunoglobulin E-mediated food allergy in high risk patients or in individuals with a poor
prognosis in terms of tolerance may benefit from new immunotherapeutic techniques such
as SOTI. The advantages of SOTI are a great decrease in the risk of serious allergic reactions
in patients with particularly severe food allergy,  and the possibility of  introducing such
foods in the patient diet – with the resulting improvement in quality of life. Further studies
are needed to better  characterize those patients  most  amenable  to  effective SOTI,  estab‐
lish the required duration of therapy, define the immunological markers for assessing the
course of treatment, the role of associated biological therapies and draft safe and effective
consensus-based protocols  and guides,  before  transferring desensitization to  the  general
clinical practice setting.
There is evidence that this new approach is changing the management paradigm in food al‐
lergy, and in our opinion, like other authors [180], possibly it´s time for the practice of SOTI
in medical centers with medical staff trained and under secure supervision of his risks.
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